FGFR2 and breast carcinoma: Also, diosgenin may primarily act over two cytoplasmic targets FGFR2 and SRC to prevent the interaction with NF-kB (prevents cell self-renewal) and metastatic spread respectively (Figure 14) and may also modulate other pathways within the breast cancer pathogenesis (Figure 15) which was evidenced during KEGG pathway analysis.